Figure S1. Effect of Tet2 ΔMye on... | Rockefeller University Press

Figure S1.

Effect of Tet2ΔMyeon hepatic fibrosis progression. (A) Treatment schedule for the construction of a CCl4-induced mouse model in systemic Tet2 KO (Tet2ΔSys) mice, hepatocyte-specific Tet2 KO (Tet2ΔAlb) mice, and myeloid cell–specific Tet2 KO (Tet2ΔMye) mice. 7-wk-old male littermates (Tet2 WT or KO) were used to construct a liver fibrosis model. (B and C) Serum levels of AST (B) and ALT (C) in different types of Tet2-deficient mice with liver fibrosis (n = 5 for each group). (D) H&E staining of livers in different types of Tet2-deficient liver fibrosis mouse models. Green arrows indicate infiltrated immune cells in liver tissues. (E) IHC staining of F4/80 in liver tissues of Tet2ΔMye mice treated with oil or CCl4 (n = 4 for each group). Scale bar, 100 μm. (F and G) IF staining (F) and statistical analysis (G) of F4/80 in liver tissues of Tet2ΔMye mice treated with oil or CCl4 (n = 4 for each group). Blue: DAPI; red: anti-F4/80. (H and I) Serum levels of AST and ALT measured by serum analyzer in CD45.1 mice before (H) and after (I) transplantation of CD11b+Tet2+/+ or CD11b+Tet2−/− myeloid cells (n = 4 for each group). (J and K) mRNA levels of Acta2 (J) and Col1a1 (K) in livers of scramble, WT-MT, and KO-MT mice (n = 4 for each group). (L) Expression levels of α-SMA and collagen I measured by western blot. (M and N) Statistical analysis of α-SMA (M) and collagen I (N)-positive area ratio for IHC staining in liver of scramble, WT-MT, and KO-MT mice (n = 4 for each group). (O) Serum levels of AST and ALT measured by serum analyzer in scramble, WT-MT, and KO-MT mice (n = 4 for each group). (P) Serum levels of HA and Col IV measured by ELISA in scramble, WT-MT, and KO-MT mice (n = 4 for each group). Data are representative of at least two independent experiments with similar results (B–O). All data are shown as mean ± SD and were analyzed by two-way ANOVA with Tukey’s multiple comparison test (B, C, and G) or one-way ANOVA with Tukey’s multiple comparison test (H–K and M–P). ***P < 0.001; **P < 0.01; *P < 0.05; P > 0.05 not significant (ns). Source data are available for this figure: SourceData FS1.

Effect of Tet2 ^ΔMye on hepatic fibrosis progression. (A) Treatment schedule for the construction of a CCl₄-induced mouse model in systemic Tet2 KO (Tet2^ΔSys) mice, hepatocyte-specific Tet2 KO (Tet2^ΔAlb) mice, and myeloid cell–specific Tet2 KO (Tet2^ΔMye) mice. 7-wk-old male littermates (Tet2 WT or KO) were used to construct a liver fibrosis model. (B and C) Serum levels of AST (B) and ALT (C) in different types of Tet2-deficient mice with liver fibrosis (n = 5 for each group). (D) H&E staining of livers in different types of Tet2-deficient liver fibrosis mouse models. Green arrows indicate infiltrated immune cells in liver tissues. (E) IHC staining of F4/80 in liver tissues of Tet2^ΔMye mice treated with oil or CCl₄ (n = 4 for each group). Scale bar, 100 μm. (F and G) IF staining (F) and statistical analysis (G) of F4/80 in liver tissues of Tet2^ΔMye mice treated with oil or CCl₄ (n = 4 for each group). Blue: DAPI; red: anti-F4/80. (H and I) Serum levels of AST and ALT measured by serum analyzer in CD45.1 mice before (H) and after (I) transplantation of CD11b⁺Tet2^+/+ or CD11b⁺Tet2^−/− myeloid cells (n = 4 for each group). (J and K) mRNA levels of Acta2 (J) and Col1a1 (K) in livers of scramble, WT-MT, and KO-MT mice (n = 4 for each group). (L) Expression levels of α-SMA and collagen I measured by western blot. (M and N) Statistical analysis of α-SMA (M) and collagen I (N)-positive area ratio for IHC staining in liver of scramble, WT-MT, and KO-MT mice (n = 4 for each group). (O) Serum levels of AST and ALT measured by serum analyzer in scramble, WT-MT, and KO-MT mice (n = 4 for each group). (P) Serum levels of HA and Col IV measured by ELISA in scramble, WT-MT, and KO-MT mice (n = 4 for each group). Data are representative of at least two independent experiments with similar results (B–O). All data are shown as mean ± SD and were analyzed by two-way ANOVA with Tukey’s multiple comparison test (B, C, and G) or one-way ANOVA with Tukey’s multiple comparison test (H–K and M–P). ***P < 0.001; **P < 0.01; *P < 0.05; P > 0.05 not significant (ns). Source data are available for this figure: SourceData FS1.

This Feature Is Available To Subscribers Only